Breakthrough Anti-cancer Drug Candidates Targeting Potential Best-in-class Therapies for 2018
PALM BEACH, Florida, February 15, 2018 /PRNewswire/ --
MarketNewsUpdates.com News Commentary
Last year was a remarkable year which saw the coming-of-age advanced oncology therapies, important advances in neurology and a record number of drug approvals. Cancer immunotherapies at large have been some of the most sought-after treatments in all of the life sciences. North America has dominated the novel drug delivery systems in the cancer therapy market in recent years whilst more and more R&D and capital enters the industry seeking the newest and most advanced therapies. Growing prevalence of cancer coupled with growing demand for personalized medicine are anticipated to propel the growth of the industry as biotech and big pharma target novel therapies and the latest, innovative treatments. The introduction of leading edge immunotherapies coupled with increasing demand for accurate diagnostic technologies are likely to trigger market growth for companies such as: Moleculin Biotech, Inc. (NASDAQ: MBRX), Nektar Therapeutics (NASDAQ: NKTR), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Pfizer Inc. (NYSE: PFE), DBV Technologies S.A. (NASDAQ: DBVT).
Moleculin Biotech, Inc. (NASDAQ: MBRX) BREAKING NEWS: Moleculin Biotech, a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some
of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that, pursuant
to its continued collaboration with MD Anderson it has developed and licensed what it believes, based on preclinical testing, is a major breakthrough in its effort to develop a new cancer treatment
that selectively kills highly resistant tumors.
"We believe our unique approach to develop immuno-stimulating STAT3 inhibitors just took a major step forward," commented Walter Klemp, Chairman and CEO of Moleculin.
"Our WP1066 portfolio has already resulted in multiple collaborations with some of the most prestigious cancer centers in the world and now this new discovery could dramatically improve our ability
to treat a broader range of the most difficult cancers, and especially pancreatic cancer."
Dr. Don Picker, Moleculin's Chief Science Officer, explained, "The scientific community recognizes the potential for small molecule immuno-stimulating STAT3
inhibitors to become a game-changer for treating cancer patients. We believe this discovery may not only dramatically improve our ability to develop and deliver such therapies, it may also help
support a new mechanistic understanding of oncogenic transcriptional activity. Specifically, we now have preclinical evidence to suggest we are capable of controlling a process known as
'ubiquitination' to block the activated form of STAT3, an important oncogenic transcription factor. The study of the role of ubiquitination in cancer is cutting edge science and appears to hold
great promise. And, given the desperate lack of treatment options for indications like pancreatic cancer, we believe clinical researchers across the country have been eagerly awaiting a
breakthrough like this." Read this and more news for Moleculin Biotech at: http://www.marketnewsupdates.com/news/mbrx.html